MMSET: Role and therapeutic opportunities in multiple myeloma

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Xie, Zhigang ^a   Chng, Wee Joo ^a,b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; HISTONE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; INTERLEUKIN 6; INTERLEUKIN 8; MULTIPLE MYELOMA SET DOMAIN; ONCOPROTEIN; PROTEIN BCL 2; SURVIVIN; UNCLASSIFIED DRUG; MESSENGER RNA;

HISTONE METHYLATION; MULTIPLE MYELOMA; PROTEIN PROTEIN INTERACTION; REVIEW; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETICS; HUMAN; PATHOLOGY; PROGNOSIS;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIPLE MYELOMA; ONCOGENE PROTEINS, FUSION; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RNA, MESSENGER; TRANSLOCATION, GENETIC;

EID: 84904792285     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/636514     Document Type: Review

References (43)

1. Rodríguez-Paredes M., Esteller M., Cancer epigenetics reaches mainstream oncology. Nature Medicine 2011 17 3 330 339 10.1038/nm.2305 2-s2.0-79952384705
2. Dawson M. A., Kouzarides T., Cancer epigenetics: from mechanism to therapy. Cell 2012 150 1 12 27 10.1016/j.cell.2012.06.013 2-s2.0-84863621527
3. Angrand P., Apiou F., Stewart A. F., Dutrillaux B., Losson R., Chambon P., NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. Genomics 2001 74 1 79 88 10.1006/geno.2001.6524 2-s2.0-0035872769 (Pubitemid 32500268)
4. Stec I., Wright T. J., van Ommen G. J., de Boer P. A., van Haeringen A., Moorman A. F., Altherr M. R., den Dunnen J. T., WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Human Molecular Genetics 1998 7 1071 1082 (Pubitemid 28306870)
5. Huang N., vom Baur E., Garnier J., Lerouge T., Vonesch J., Lutz Y., Chambon P., Losson R., Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators. The EMBO Journal 1998 17 12 3398 3412 10.1093/emboj/17.12.3398 2-s2.0-0032526951 (Pubitemid 28279513)
6. Chesi M., Nardini E., Lim R. S. C., Smith K. D., Michael Kuehl W., Bergsagel P. L., The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998 92 9 3025 3034 2-s2.0-0032212243 (Pubitemid 28492306)
7. Garlisi C. G., Uss A. S., Xiao H., Tian F., Sheridan K. E., Wang L., Billah M. M., Egan R. W., Stranick K. S., Umland S. P., A unique mRNA initiated within a middle intron of WHSC1/MMSET encodes a DNA binding protein that suppresses human IL-5 transcription. American Journal of Respiratory Cell and Molecular Biology 2001 24 1 90 98 10.1165/ajrcmb.24.1.4224 2-s2.0-0035146045 (Pubitemid 32097512)
8. Peña P. V., Davrazou F., Shi X., Walter K. L., Verkhusha V. V., Gozani O., Zhao R., Kutateladze T. G., Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2. Nature 2006 442 7098 100 103 10.1038/nature04814 2-s2.0-33745818717 (Pubitemid 44064217)
9. Wu H., Zeng H., Lam R., Tempel W., Amaya M. F., Xu C., Dombrovski L., Qiu W., Wang Y., Min J., Structural and histone binding ability characterizations of human PWWP domains. PLoS ONE 2011 6 6 e18919 10.1371/journal.pone.0018919 2-s2.0-79959494918
10. Huang Z., Wu H., Chuai S., Xu F., Yan F., Englund N., Wang Z., Zhang H., Fang M., Wang Y., Gu J., Zhang M., Yang T., Zhao K., Yu Y., Dai J., Yi W., Zhou S., Li Q., Wu J., Liu J., Wu X., Chan H., Lu C., Atadja P., Li E., Hu M., NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma. Cancer Research 2013 73 6277 6288 10.1158/0008-5472.CAN-13-1000
11. Štros M., Launholt D., Grasser K. D., The HMG-box: a versatile protein domain occurring in a wide variety of DNA-binding proteins. Cellular and Molecular Life Sciences 2007 64 19-20 2590 2606 10.1007/s00018-007-7162-3 2-s2.0-34548549334 (Pubitemid 350035606)
12. Keats J. J., Maxwell C. A., Taylor B. J., Hendzel M. J., Chesi M., Bergsagel P. L., Larratt L. M., Mant M. J., Reiman T., Belch A. R., Pilarski L. M., Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood 2005 105 10 4060 4069 10.1182/blood-2004-09-3704 2-s2.0-20844463416 (Pubitemid 40656156)
13. Lauring J., Abukhdeir A. M., Konishi H., Garay J. P., Gustin J. P., Wang Q., Arceci R. J., Matsui W., Park B. H., The multiple myeloma-associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood 2008 111 2 856 864 10.1182/blood-2007-05-088674 2-s2.0-38349087546
14. Bergsagel P. L., Kuehl W. M., Molecular pathogenesis and a consequent classification of multiple myeloma. Journal of Clinical Oncology 2005 23 26 6333 6338 10.1200/JCO.2005.05.021 2-s2.0-27244445489 (Pubitemid 46218843)
15. Bergsagel P. L., Kuehl W. M., Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunological Reviews 2003 194 96 104 10.1034/j.1600-065X.2003.00052.x 2-s2.0-0038675193 (Pubitemid 36886431)
16. Keats J. J., Reiman T., Belch A. R., Pilarski L. M., Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leukemia and Lymphoma 2006 47 11 2289 2300 10.1080/10428190600822128 2-s2.0-33751075190 (Pubitemid 44768421)
17. Keats J. J., Reiman T., Maxwell C. A., Taylor B. J., Larratt L. M., Mant M. J., Belch A. R., Pilarski L. M., In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003 101 4 1520 1529 10.1182/blood-2002-06-1675 2-s2.0-0037441747 (Pubitemid 36182529)
18. Santra M., Zhan F., Tian E., Barlogie B., Shaughnessy J. Jr., A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 2003 101 6 2374 2376 10.1182/blood-2002-09-2801 2-s2.0-0037443417 (Pubitemid 36302083)
19. Marango J., Shimoyama M., Nishio H., Meyer J. A., Min D., Sirulnik A., Martinez-Martinez Y., Chesi M., Bergsagel P. L., Zhou M., Waxman S., Leibovitch B. A., Walsh M. J., Licht J. D., The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 2008 111 6 3145 3154 10.1182/blood-2007-06-092122 2-s2.0-42449161943
20. Brito J. L. R., Walker B., Jenner M., Dickens N. J., Brown N. J. M., Ross F. M., Avramidou A., Irving J. A. E., Gonzalez D., Davies F. E., Morgan G. J., MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica 2009 94 1 78 86 10.3324/haematol. 13426 2-s2.0-58149232433
21. Martinez-Garcia E., Popovic R., Min D., Sweet S. M. M., Thomas P. M., Zamdborg L., Heffner A., Will C., Lamy L., Staudt L. M., Levens D. L., Kelleher N. L., Licht J. D., The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2011 117 1 211 220 10.1182/blood-2010-07-298349 2-s2.0-78650978001
22. Kuo A. J., Cheung P., Chen K., Zee B. M., Kioi M., Lauring J., Xi Y., Park B. H., Shi X., Garcia B. A., Li W., Gozani O., NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Molecular Cell 2011 44 4 609 620 10.1016/j.molcel.2011.08.042 2-s2.0-81355133161
23. Kassambara A., Klein B., Moreaux J., MMSET is overexpressed in cancers: link with tumor aggressiveness. Biochemical and Biophysical Research Communications 2009 379 4 840 845 10.1016/j.bbrc.2008.12.093 2-s2.0-58949087354
24. Morishita M., di Luccio E., Cancers and the NSD family of histone lysine methyltransferases. Biochimica et Biophysica Acta 2011 1816 2 158 163 10.1016/j.bbcan.2011.05.004 2-s2.0-79959272481
25. Sun X. J., Wei J., Wu X. Y., Hu M., Wang L., Wang H. H., Zhang Q. H., Chen S. J., Huang Q. H., Chen Z., Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase. Journal of Biological Chemistry 2005 280 42 35261 35271 10.1074/jbc.M504012200 2-s2.0-27444436367 (Pubitemid 41532714)
26. Kang H. B., Choi Y., Lee J. M., Choi K. C., Kim H. C., Yoo J. Y., Lee Y. H., Yoon H. G., The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription. FEBS Letters 2009 583 12 1880 1886 10.1016/j.febslet.2009.05.038 2-s2.0-67349115185
27. Kim J. Y., Hae J. K., Choe N. W., Kim S. M., Eom G. H., Hee J. B., Kook H., Seo S. B., Multiple myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Molecular and Cellular Biology 2008 28 6 2023 2034 10.1128/MCB.02130-07 2-s2.0-40349098063 (Pubitemid 351342632)
28. Li Y., Trojer P., Xu C., Cheung P., Kuo A., Drury W. J. III, Qiao Q., Neubert T. A., Xu R., Gozani O., Reinberg D., The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. The Journal of Biological Chemistry 2009 284 49 34283 34295 10.1074/jbc.M109.034462 2-s2.0-71749121455
29. Nimura K., Ura K., Shiratori H., Ikawa M., Okabe M., Schwartz R. J., Kaneda Y., A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature 2009 460 7252 287 291 10.1038/nature08086 2-s2.0-67650461956
30. Pei H., Zhang L., Luo K., Qin Y., Chesi M., Fei F., Bergsagel P. L., Wang L., You Z., Lou Z., MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 2011 470 7332 124 128 10.1038/nature09658 2-s2.0-79551665780
31. Todoerti K., Ronchetti D., Agnelli L., Castellani S., Marelli S., Deliliers G. L., Zanella A., Lombardi L., Neri A., Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma. British Journal of Haematology 2005 131 2 214 218 10.1111/j.1365-2141.2005.05741.x 2-s2.0-32944460060 (Pubitemid 43899688)
32. Binda O., On your histone mark, SET, methylate! Epigenetics 2013 8 5 457 463 10.4161/epi.24451 2-s2.0-84877322025
33. Min D. J., Ezponda T., Kim M. K., Will C. M., Martinez-Garcia E., Popovic R., Basrur V., Elenitoba-Johnson K. S., Licht J. D., MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC. Leukemia 2013 27 3 686 694 10.1038/leu.2012.269 2-s2.0-84875216520
34. Xie Z., Gunaratne J., Cheong L. L., Liu S. C., Koh T. L., Huang G., Blackstock W. P., Chng W. J., Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma. Oncotarget 2013 4 7 1008 1018
35. Toyokawa G., Cho H., Masuda K., Yamane Y., Yoshimatsu M., Hayami S., Takawa M., Iwai Y., Daigo Y., Tsuchiya E., Tsunoda T., Field H. I., Kelly J. D., Neal D. E., Maehara Y., Ponder B. A. J., Nakamura Y., Hamamoto R., Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the WNT pathway. Neoplasia 2011 13 10 887 898 10.1593/neo.11048 2-s2.0-80054818729
36. Yang P., Guo L., Duan Z. J., Tepper C. G., Xue L., Chen X., Kung H., Gao A. C., Zou J. X., Chena H., Histone methyltransferase NSD2/MMSET mediates constitutive NF-kb signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Molecular and Cellular Biology 2012 32 15 3121 3131 10.1128/MCB.00204-12 2-s2.0-84864627631
37. Ezponda T., Popovic R., Shah M. Y., Martinez-Garcia E., Zheng Y., Min D.-., Will C., Neri A., Kelleher N. L., Yu J., Licht J. D., The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene 2013 32 23 2882 2890 10.1038/onc.2012.297 2-s2.0-84879414983
38. Cao F., Townsend E. C., Karatas H., Xu J., Li L., Lee S., Liu L., Chen Y., Ouillette P., Zhu J., Hess J. L., Atadja P., Lei M., Qin Z. S., Malek S., Wang S., Dou Y., Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Molecular Cell 2014 53 2 247 261 10.1016/j.molcel.2013.12.001
39. Smith E. M., Boyd K., Davies F. E., The potential role of epigenetic therapy in multiple myeloma. British Journal of Haematology 2010 148 5 702 713 10.1111/j.1365-2141.2009.07976.x 2-s2.0-76449105686
40. Kim D. H., Rossi J. J., Strategies for silencing human disease using RNA interference. Nature Reviews Genetics 2007 8 3 173 184 10.1038/nrg2006 2-s2.0-33847036990
41. Pirollo K. F., Chang E. H., Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Research 2008 68 5 1247 1250 10.1158/0008-5472.CAN-07-5810 2-s2.0-40449083756 (Pubitemid 351346828)
42. Rajkumar S. V., Treatment of multiple myeloma. Nature Reviews Clinical Oncology 2011 8 8 479 491 10.1038/nrclinonc.2011.63 2-s2.0-79961027391
43. Mateos M. V., Ocio E. M., San Miguel J. F., Novel generation of agents with proven clinical activity in multiple myeloma. Seminars in Oncology 2013 40 618 633